Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Current Deferred Revenue (2016 - 2021)

Syndax Pharmaceuticals (SNDX) has 7 years of Current Deferred Revenue data on record, last reported at $12.4 million in Q3 2021.

  • For Q3 2021, Current Deferred Revenue rose 717.4% year-over-year to $12.4 million; the TTM value through Sep 2021 reached $12.4 million, up 717.4%, while the annual FY2020 figure was $1.5 million, 0.0% changed from the prior year.
  • Current Deferred Revenue reached $12.4 million in Q3 2021 per SNDX's latest filing, up from $1.5 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $12.4 million in Q3 2021 and bottomed at $1.2 million in Q1 2017.
  • Average Current Deferred Revenue over 5 years is $2.0 million, with a median of $1.5 million recorded in 2018.
  • Peak YoY movement for Current Deferred Revenue: decreased 3.56% in 2018, then skyrocketed 717.4% in 2021.
  • A 5-year view of Current Deferred Revenue shows it stood at $1.6 million in 2017, then dropped by 3.56% to $1.5 million in 2018, then changed by 0.0% to $1.5 million in 2019, then changed by 0.0% to $1.5 million in 2020, then surged by 717.4% to $12.4 million in 2021.
  • Per Business Quant database, its latest 3 readings for Current Deferred Revenue were $12.4 million in Q3 2021, $1.5 million in Q2 2021, and $1.5 million in Q1 2021.